Cellbyte Raises $2.75 Million to Cut Pharmaceutical Drug Launch Timelines in Half with AI

Cellbyte, AI agents for pharmaceutical drug launches, led by Felix Steinbrenner, Daniel Moreira, and Samuel M., has secured $2.75 million in seed funding led by Frontline Ventures, with participation from Y Combinator, Pace Ventures, Saras Capital, and Springboard Health Angels. 

Fragmented data slows drug launches, leaving patients waiting over a year for life-saving treatments. Market Access teams spend a huge amount of time and money assembling regulatory, pricing, and reimbursement documentation.

Cellbyte delivers an AI-native platform that analyses millions of clinical, pricing, HTA, regulatory, and internal data points in real time. It provides deep, reliable insights that accelerate documentation, launch sequencing, and go-to-market strategy.

Legacy databases offer shallow, outdated information. Cellbyte delivers a comprehensive, always-updated data foundation, turning months of work into minutes without compromising quality.

Founded in 2024 by Daniel Moreira, Felix Steinbrenner, and Samuel Moreira, Cellbyte combines deep pharma expertise with strong AI and company-building experience. The company has quickly gained traction, hitting six-figure ARR within weeks, expanding into major global markets, and signing customers including Bayer.

With new funding, Cellbyte will scale its team and engineering capabilities to meet growing demand and continue its momentum toward becoming the operating system for commercial pharma teams worldwide.

Felix Steinbrenner, Co-CEO, said: “A drug’s launch depends on fast, accurate insights. Our traction with major pharma companies shows the industry is ready for a faster, higher-quality, and more cost-effective way to launch drugs.”

Daniel Moreira, Co-CEO, said: “While clinical development has modernized, Pricing and Market Access still rely on manual, fragmented work. Generative AI is changing that, and Cellbyte is driving the shift.”